Nuvation Bio Inc.

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on oncology that entered the public markets through a de-SPAC merger with Panacea Acquisition Corp. II, a blank-check vehicle sponsored by Panacea Holdings that completed its IPO in 2021. Panacea Acquisition Corp. II traded on the New York Stock Exchange under the ticker PANA before the transaction closed, after which the combined entity began trading as NUVB. The company filed an amended annual report on Form 10-K/A with the SEC on May 21, 2021, reflecting supplemental disclosures to its previously submitted filing. Nuvation Bio operates in the healthcare and biopharmaceutical sector with a pipeline targeting difficult-to-treat cancer biology. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal analytics on this and hundreds of other SPAC transactions.